Gilead Sciences, Inc.

GILD · Nasdaq · ·

Compară

167,97 USD-1,0 %închidere 12 nov.

Cifre până la 30 septembrie 2026, din 10-Q depus pe 30 octombrie 2026

1W: +0,6 %
1M: +9,4 %

Acțiuni Gilead Sciences, Inc. (GILD) — este o companie bună? — InspectStocks

Gilead Sciences, Inc.

GILD · Nasdaq · ·

Compară

167,97 USD-1,0 %închidere 12 nov.

Cifre până la 30 septembrie 2026, din 10-Q depus pe 30 octombrie 2026

1W: +0,6 %
1M: +9,4 %

Just reported

Q3 2026 results

From Gilead Sciences's results release of 29 octombrie 2026; its quarterly report has since been filed.

Revenue
Actual
8,3B USD
+6,8 % y/y
+6,4 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
1,94 USD
-20 % y/y
Guided
—
No guide given
Operating income, GAAP
Actual
3,46B USD
+4,1 % y/y
Guided
—
No guide given

Company outlook

Full year 2026

EPS, GAAP9,88 USD+46 % y/y Raised +8,8 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Gilead Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Selecție
Biotech
De la InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Preț, 1 an
+28,4 %
Venituri, 1 an
+12,9 %
+13
A 8B 4C 5D 1F 1

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Cum face bani

HIV medicines73 %
Liver disease medicines11 %
Cancer medicines11 %
Veklury1 %
Royalties, contracts, and other revenue1 %

Ponderile din venituri sunt estimări pentru six months ended June 30, 2026, nu cifre dintr-un raport depus.

Concurează cu

Ce vinde6

Biktarvy
A daily tablet used to treat HIV infection in certain patients.
Yeztugo
A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
Descovy
A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.

Afișează încă 3

Trodelvy
An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
Yescarta
A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
Livdelzi
An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.

Cine cumpără4

In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

1Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
2It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
3Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.
4Sales depend on health insurers and government payers covering medicines and on the prices and discounts they accept.

Ce ar putea merge prost

1HIV medicines accounted for 72.6% of revenue (six months ended June 30, 2026, high), so changes in demand, competition, coverage, or pricing for those medicines could materially affect sales.
2Clinical trials can fail or be delayed, and regulators can limit or reject a medicine's use. In June 2026, Gilead stopped a Trodelvy study in non-small cell lung cancer and recorded a $1.75 billion impairment charge for the related research asset (three months ended June 30, 2026, high).
3Generic medicines, competing treatments, patent challenges, and required discounts or rebates can reduce sales or the amount Gilead receives for its medicines.

Situațiile financiare complete →

Despre Gilead Sciences, Inc.

Gilead discovers, develops, and sells prescription medicines. Its medicines prevent or treat human immunodeficiency virus (HIV), viral hepatitis, cancer, coronavirus disease 2019 (COVID-19), and other serious illnesses. It sells medicines directly through its commercial teams and through wholesalers, distributors, and business partners.

Sediu: Foster City, California
Înființată în: 1987
Angajați: Approximately 17,000 (December 31, 2025, high)
Listată la: Nasdaq
Sfârșitul exercițiului financiar: December 31

Construit din raportările proprii ale Gilead Sciences, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.

Just reported